$天境生物(IMAB)$ Target Price: $17.93On Mar 13, I-Mab announced that it would initiate the development of TJM2 to treat cytokine storm (CS) in patients with severe coronavirus infection.TJM2, indicated for RA and side effects of CAR-T related therapies, is in Phase I clinical trial in US and could initiate Phase I trial in China in early 2020.TJM2 could potentially treat severely affected patients of coronavirus through neutralizing increased cytokines.Initiating the development of TJM2 for the treatment of CS associated with severe coronavirus infection.On March 13, I-Mab announced it has started the development of TJM2 for the treatment of CS in patients seriously sick with coronavirus. According to the company, the study will kick

$天境生物(IMAB)$ PRICE TARGET (PT) $16.00GILD just announced a takeout deal of FTSV for $4.9B. Another CD47 player TRIL seesits share rising up substantially following the news (~50%). We see intrigued interest ofCD47-SIRPα landscape and review the current progress from leading programs in thespace. Also, we highlight IMAB's TJC4, a CD47 antibody differentiated on safety. Its Ph1readout in 2H '20 could serve as a meaningful catalyst, and we see 30-40% upside ifsafety plays out in human trials.CD47-Sirpα Space is Heating Up with Three Companies Leading the Pack:We screened both public and private companies and summarized >20 CD47- or Sirpα-targeting programs in the space (see our report here). Three companies have reported encourag